These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 17990351)

  • 41. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
    Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ
    Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [New medications; bevacizumab].
    Cohen AF; van Bronswijk H
    Ned Tijdschr Geneeskd; 2006 Oct; 150(40):2194-5. PubMed ID: 17061430
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Therapeutic strategies using VEGF inhibitors in colorectal cancer].
    Boige V; Malka D; Ducreux M
    Bull Cancer; 2005 Aug; 92(Spec no):S29-36. PubMed ID: 16387667
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting vascular endothelial growth factor pathway in first-line treatment of metastatic colorectal cancer: state-of-the-art and future perspectives in clinical and molecular selection of patients.
    Loupakis F; Bocci G; Pasqualetti G; Fornaro L; Salvatore L; Cremolini C; Masi G; Danesi R; Del Tacca M; Falcone A
    Curr Cancer Drug Targets; 2010 Feb; 10(1):37-45. PubMed ID: 20088795
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
    Köhne CH; Lenz HJ
    Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
    Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Spotlight on bevacizumab in metastatic colorectal cancer.
    McCormack PL; Keam SJ
    BioDrugs; 2008; 22(5):339-41. PubMed ID: 18778115
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
    Fernando NH; Hurwitz HI
    Oncologist; 2004; 9 Suppl 1():11-8. PubMed ID: 15178811
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of targeted therapy in the treatment of colorectal cancer.
    Goldberg RM; Hurwitz HI; Fuchs CS
    Clin Adv Hematol Oncol; 2006 Aug; 4(8 Suppl 17):1-10; quiz 11-2. PubMed ID: 17139241
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses?
    Abbadessa G; Vogiatzi P; Rimassa L; Claudio PP
    Drug News Perspect; 2007 Jun; 20(5):307-13. PubMed ID: 17878958
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The horizon of antiangiogenic therapy for colorectal cancer.
    Olszewski AJ; Grossbard ML; Kozuch PS
    Oncology (Williston Park); 2005 Mar; 19(3):297-306; discussion 306, 308, 317-33. PubMed ID: 15828549
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
    Wagner AD; Thomssen C; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Angiogenesis targeting in gastro-intestinal cancers].
    Meric JB
    Bull Cancer; 2007; 94(7 Suppl):F207-15. PubMed ID: 17964998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Antiangiogenic therapy for gastrointestinal tumors].
    Lakatos G; Tulassay Z
    Orv Hetil; 2008 Dec; 149(49):2317-24. PubMed ID: 19042183
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.
    Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D
    Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Managing patients with metastatic colorectal cancer on bevacizumab.
    Lemmens L; Claes V; Uzzell M
    Br J Nurs; 2008 Aug 14-Sep 10; 17(15):944-9. PubMed ID: 18983014
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emerging therapies for metastatic colorectal cancer: focus on EGFR and VEGF inhibition.
    Venook AP
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S74-84. PubMed ID: 19780248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.